ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted ...

ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted ...

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology’s proprietary linker-payload platformALX2004, the company’s first ADC, was fully designed and developed in-house by ALX Oncology scientistsCompany…

ALX Oncology's ALX2004 gains FDA IND clearance to treat solid tumours

ALX2004 has been designed using the company’s topoisomerase I inhibitor payload platform to enhance anti-tumour activity and improve patient outcomes in EGFR-expressing tumours. The molecule, developed entirely within The post ALX Oncology’s ALX2004 gains FDA IND clearance to treat solid tumours appeared first on Pharmaceutical Business review.

FDA Advances ALX2004 to Phase 1 Trials in EGFR+ Solid Tumors

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for EGFR+ solid tumors.